Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BMS-986318
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
BMS-986318 is a potent, orally administered, nonbile acid small molecule agonist of the farnesoid X receptor (FXR), a nuclear hormone receptor involved in bile acid regulation and metabolic homeostasis. It was developed by Bristol Myers Squibb for the treatment of liver diseases such as nonalcoholic steatohepatitis (NASH), liver cholestasis, and fibrosis. Preclinical studies demonstrated that BMS-986318 activates FXR both in vitro and in vivo, showing efficacy in mouse models of liver cholestasis and fibrosis with favorable ADME properties. The compound is designed to offer an alternative to bile acid-derived FXR agonists, potentially reducing adverse effects like hepatotoxicity and pruritus observed with other agents[1][5][6][7].
02
Targets
FXR (Farnesoid x-activated receptor)
Beyond the preview
Go deeper on BMS-986318.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BMS-986318.